Protalix BioTherapeutics, Inc. (PLX): Total Assets
$82.35M
As of 2025-12-31
$110.34M
As of 2026-06-30
+13.9%
3-year compound annual growth
+3.9%
5-year compound annual growth
-1.7%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $82.35M | +12.2% | 2026-03-18, Balance as of period end |
| 2024-12-31 | $73.42M | -13.0% | 2026-03-18, Balance as of period end |
| 2023-12-31 | $84.43M | +51.4% | 2025-03-17, Balance as of period end |
| 2022-12-31 | $55.79M | -24.3% | 2024-03-14, Balance as of period end |
| 2021-12-31 | $73.67M | +8.4% | 2023-02-27, Balance as of period end |
| 2020-12-31 | $67.93M | +49.7% | 2022-03-31, Balance as of period end |
| 2019-12-31 | $45.39M | -25.7% | 2021-03-30, Balance as of period end |
| 2018-12-31 | $61.13M | -15.3% | 2020-03-12, Balance as of period end |
| 2017-12-31 | $72.21M | -12.2% | 2019-03-18, Balance as of period end |
| 2016-12-31 | $82.25M | -15.4% | 2018-03-06, Balance as of period end |
| 2015-12-31 | $97.25M | +24.1% | 2017-03-16, Balance as of period end |
| 2014-12-31 | $78.36M | -30.9% | 2016-03-08, Balance as of period end |
| 2013-12-31 | $113.33M | +44.0% | 2015-03-12, Balance as of period end |
| 2012-12-31 | $78.73M | +52.0% | 2014-03-13, Balance as of period end |
| 2011-12-31 | $51.80M | -20.0% | 2013-02-28, Balance as of period end |
| 2010-12-31 | $64.73M | n/a | 2012-02-27, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $82.35M | +12.2% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $276.88M | +113.8% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $26.99M | -16.6% |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $70.55M | +57.0% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $1.00B | -28.3% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $186.53M | -45.4% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $252.28M | -35.8% |
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $143.01M | +16.6% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $59.74M | -41.2% |
Compare PLX, IVVD, CSBR, FENC side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗